As of July 18, 2026, Endomorphin-1 is legal to sell at retail in Montana. Unscheduled - legal as research-use-only; no operative instrument reaches a structurally-dissimilar opioid peptide. Controlling source: MCA 50-32-101 (dangerous drug analogue).
Verified July 18, 2026 · confidence: confirmedEndomorphin-1 (Tyr-Pro-Trp-Phe-NH2) is not named or scheduled in Montana. The state has a controlled-substance analogue/designer-drug statute whose effect prong can satisfy the test without structural similarity. It still does not operatively reach EM-1 as sold (see effect-prong scope / 'specifically designed' / human-consumption gate in the detail). Controlling instrument reviewed: MCA 50-32-101 (dangerous drug analogue). Conclusion: no operative instrument reaches a structurally-dissimilar endogenous opioid peptide; status LEGAL at the state controlled-substances level. Residual risk: low. Federal floor still applies (Analogue Act human-consumption contingency + FD&C unapproved-new-drug).
MCA 50-32-101(7)(a): "'Dangerous drug analogue' means any material ... that is structurally related to or chemically derived from any dangerous drug in Schedules I through V ..., OR that is expressly or impliedly represented to produce or does produce a physiological effect similar to or greater than the effect of a dangerous drug ..." (b) excludes scheduled/FDA-approved/excepted substances. [Effect prong gated by representation; 'structurally related' fails for a peptide.]
Among Montana's 4 neighbors, Idaho, North Dakota, South Dakota and Wyoming are legal, the same posture as Montana.
Open the interactive map · Every compound in Montana
Not federally scheduled. Endomorphin-1 - not federally scheduled; endogenous opioid tetrapeptide, no CSA entry and no analogue-act structural hook Federal detail
2 instruments on file for this compound's framework in Montana; 2 of 2 citations above are official sources. Each text carries its source and a fingerprint that changes when the law does.
2aaa76f87ec35fee**50-32-222(4) Hallucinogenic substances (header)** — "Unless specifically excepted or listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following is a hallucinogenic substance, including salts, isomers, and salts of isomers whenever the existence of those salts, isomers, and salts of isomers is possible within the specific chemical designation: … (dd) psilocybin; (ee) psilocyn, also known as psilocin; …" — MCA 50-32-222(4), https://mca.legmt.gov/bills/mca/title_0500/chapter_0320/part_0020/section_0220/0500-0320-0020-0220.html (official Montana Code Annotated 2025). 4-HO-MET (4-hydroxy-N-methyl-N-ethyltryptamine) does **not** appear anywhere in the enumerated list; the listed 4-/5-substituted tryptamines are bufotenine, 5-MeO-DIPT, 5-MeO-DMT, AMT, AET, DET, DMT — not 4-HO-MET. **50-32-222(5)(a)** — "For the purposes of subsection (4), the term 'isomer' includes the optical, positional, and geometric isomers." — same URL (confirms the schedule's only catch-all reach is isomers, not homologs). **50-32-222(11) Dangerous drug analogues** — "Unless specifically excepted or listed in another schedule, this designation includes any material, compound, mixture, or preparation defined in 50-32-101 as a dangerous drug analogue." — same URL. **50-32-101(7)(a)** — "'Dangerous drug analogue' means any material, compound, mixture, or preparation that is structurally related to or chemically derived from any dangerous drug in Schedules I through V set forth in Title 50, chapter 32, part 2, or that is expressly or impliedly represented to produce or does produce a physiological effect similar to or greater than the effect of a dangerous drug in Schedules I through V." — MCA 50-32-101(7)(a), https://mca.legmt.gov/bills/mca/title_0500/chapter_0320/part_0010/section_0010/0500-0320-0010-0010.html (official MCA 2025).
e7b1283b8435665050-32-222(11) Dangerous drug analogues. Unless specifically excepted or listed in another schedule, this designation includes any material, compound, mixture, or preparation defined in 50-32-101 as a dangerous drug analogue. 50-32-101(7)(a) "Dangerous drug analogue" means any material, compound, mixture, or preparation that is structurally related to or chemically derived from any dangerous drug in Schedules I through V set forth in Title 50, chapter 32, part 2, or that is expressly or impliedly represented to produce or does produce a physiological effect similar to or greater than the effect of a dangerous drug in Schedules I through V. (b) The term does not include any material, compound, mixture, or preparation that is currently listed as a dangerous drug in Schedules I through V set forth in Title 50, chapter 32, part 2, or in an administrative rule, that is approved for use by the United States food and drug administration, or that is otherwise specifically excepted from Title 50, chapter 32, part 2.
Compound Laws, published by Compound Analytics, reports the record: statutes verbatim, official citations, enforcement facts and verification dates. Nothing here is legal advice and nothing here describes how to get around a law. A jurisdiction with no verified row is reported as not yet verified, never as legal. Found an error? Corrections policy.
About · Methodology · Glossary · Changes · Data & API · llms.txt · Sitemap